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Abstract
Aims/hypothesis Upon stimulation of insulin signalling or
contraction-induced AMP-activated protein kinase (AMPK)
activation, the glucose transporter GLUT4 and the long-
chain fatty acid (LCFA) transporter CD36 similarly
translocate from intracellular compartments to the plasma
membrane of cardiomyocytes to increase uptake of glucose
and LCFA, respectively. This similarity in regulation of
GLUT4 traffic and CD36 traffic suggests that the same
families of trafficking proteins, including vesicle-associated
membrane proteins (VAMPs), are involved in both pro-
cesses. While several VAMPs have been implicated in
GLUT4 traffic, nothing is known about the putative
function of VAMPs in CD36 traffic. Therefore, we
compared the involvement of the myocardially produced
VAMP isoforms in insulin- or contraction-induced GLUT4
and CD36 translocation.
Methods Five VAMP isoforms were silenced in HL-1
cardiomyocytes. The cells were treated with insulin or the
contraction-like AMPK activator oligomycin or were
electrically stimulated to contract. Subsequently, GLUT4
and CD36 translocation as well as substrate uptake were
measured.
Results Three VAMPs were demonstrated to be necessary
for both GLUT4 and CD36 translocation, either specifically
in insulin-treated cells (VAMP2, VAMP5) or in oligomycin/
contraction-treated cells (VAMP3). In addition, there are
VAMPs specifically involved in either GLUT4 traffic
(VAMP7 mediates basal GLUT4 retention) or CD36 traffic
(VAMP4 mediates insulin- and oligomycin/contraction-
induced CD36 translocation).
Conclusions/interpretation The involvement of distinct
VAMP isoforms in both GLUT4 and CD36 translocation
indicates that CD36 translocation, just like GLUT4 trans-
location, is a vesicle-mediated process dependent on
soluble N-ethylmaleimide-sensitive factor attachment pro-
tein receptor (SNARE) complex formation. The ability of
other VAMPs to discriminate between GLUT4 and CD36
translocation allows the notion that myocardial substrate
preference can be modulated by these VAMPs.
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Introduction
Glucose and long-chain fatty acids (LCFA) are the predom-
inant substrates for energy provision of the contracting heart.
The major cardiac substrate transporters in the heart are
GLUT4 (glucose) and CD36 (LCFA), both of which cycle
between intracellular stores and the plasma membrane (for
review see Schwenk et al. [1]). Translocation of GLUT4 and
CD36 to the plasma membrane is induced under conditions of
elevated insulin levels (e.g. postprandially) and under con-
ditions of increased ATP demand (e.g. upon increased
contraction), involving activation of insulin signalling and
AMP-activated protein kinase (AMPK), respectively.
In the early insulin-resistant heart there is a permanent
relocation of CD36 from endosomes to the plasma membrane
while GLUT4 distribution appears not yet affected [2]. The
constantly elevated presence of CD36 at the plasma
membrane fuels a vicious cycle of increased CD36-
mediated LCFA uptake and subsequent accumulation of toxic
lipid metabolites (lipotoxicity) [2, 3]. Over time, lipotoxicity
will lead to aggravation of insulin resistance, and finally to
cardiac dysfunction [4]. In order to explain the selective
increase in sarcolemmal content of CD36 in the early insulin-
resistant heart, there must be alterations in the trafficking
machinery of CD36. Given that sarcolemmal CD36 reloca-
tion is an early key event in diabetes-related cardiac
dysfunction, it is of pivotal importance to identify the
trafficking machinery involved in the subcellular distribution
of CD36, especially in relation to that of GLUT4.
The subcellular distribution of GLUT4 and CD36 is
regulated by soluble N-ethylmaleimide-sensitive factor
(NSF) attachment protein receptors (SNAREs), the mech-
anistical core complexes of membrane fusion [5]. Histori-
cally, SNAREs have been classified into vesicle-associated
SNAREs (v-SNAREs) and target-membrane-associated
SNAREs (t-SNAREs). However, more recent classifica-
tions reflect the conserved amino-acid residues within the
SNARE motifs, which are either a glutamine (Q-SNAREs)
or an arginine (R-SNAREs). When the vesicle-associated
R-SNAREs interact with a specific subset of Q-SNAREs at
the target membrane, a hetero-oligomeric SNARE complex
is formed that catalyses the fusion of the vesicle with the
target membrane.
While there are several subfamilies of t-SNAREs
(syntaxins, SNAPs, Sec proteins), vesicle-associated mem-
brane proteins (VAMPs) represent all members of the v-
SNARE subfamily [5]. There are seven identified VAMP
isoforms: VAMP1/synaptobrevin1, which is involved in
synaptic vesicle fusion [6] and appears to be absent in
muscle tissues [7]; VAMP2/synaptobrevin2; VAMP3/cellu-
brevin; VAMP4; VAMP5/myobrevin, which is predomi-
nantly produced in heart and skeletal muscle [8]; VAMP7/
TI-VAMP; and VAMP8/endobrevin [5]. Insulin-stimulated
translocation of GLUT4 involves VAMP2, which interacts
with the t-SNAREs syntaxin4 and SNAP23 at the plasma
membrane [9, 10]. Furthermore, VAMP7 has been shown to
mediate GLUT4 translocation on hyperosmotic shock [11].
These findings suggest that different VAMP isoforms might
be involved in the translocation of GLUT4 upon different
stimuli. However, nothing is known about the role of
VAMPs in CD36 trafficking.
The purpose of this study was to investigate the
involvement of each of the myocardial VAMPs in insulin-
and contraction-stimulated GLUT4 and CD36 translocation
to the plasma membrane. HL-1 atrial cardiomyocytes were
used in which the genes encoding the different VAMP
isoforms were transiently knocked down using small
interfering RNAs (siRNAs). In these cells, plasmalemmal
GLUT4 and CD36, as well as glucose and palmitate uptake,
were measured after activation of insulin or contraction
signalling. The data presented in this study disclose the
involvement of distinct VAMPs in the cellular distribution
of GLUT4 and CD36 and their importance for the insulin-
and contraction-stimulated translocation of both transporters
to the plasma membrane of cardiomyocytes.
Methods
Antibodies, siRNAs and plasmids Antibodies against
VAMP2 and VAMP3 were obtained from Abcam (Cam-
bridge, UK), against VAMP4 from Novus Biologicals (Lit-
tleton, CO, USA), against VAMP5 from Synaptic Systems
(Göttingen, Germany) and against VAMP7 and GLUT4 from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
bodiesagainst the myc epitope, protein kinaseB (PKB/AKT),
phospho-PKB/AKT(Ser473), phospho-acetyl-coA carboxyl-
ase (pACC; Ser79), phospho-AMPKα (pAMPK; Thr172)
and cleaved caspase-3 were from Cell Signaling (Danvers,
MA, USA), and against mouse CD36 from Chemicon
(Billerica, MA, USA). siRNAs against VAMP2/synaptobre-
vin2 (CCGATCTTTCCCTTATCTTtt), VAMP3/cellubrevin
(GCTCATGCTCTTATGTTAGtt), VAMP4 (CGTACGTTTG
AGCTTATAAtt), VAMP5/myobrevin (GGGAAGGCT
GAATGACTGCtt) and VAMP7/TI-VAMP (GGAAATTC
ATGTGACTATGtt) were from Ambion (Applied Biosys-
2210 Diabetologia (2010) 53:2209–2219tems, Austin, TX, USA). The plasmid coding for GLUT4myc
was kindly provided by J. Eckel (German Diabetes Center,
Düsseldorf, Germany).
Cell culture of HL-1 atrial cardiomyocytes HL-1 cells were
kindly provided by W. Claycomb (Louisiana State University,
New Orleans, LA, USA), cultured in Claycomb medium
(supplemented with 10% FCS, 0.1 mmol/l noradrenaline
[norepinephrine], 2 mmol/l L-glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin) at 37°C and 5% CO2.C e l l s
were split twice a week after reaching confluence.
Electric-field stimulation HL-1 cells were electrically paced
using the C-Pace Stimulator and six-well C-Dish Culture
Dish Electrodes from IonOptix (Milton, MA, USA). Prior
to electric-field stimulation, cells were incubated in deple-
tion medium (DMEM low glucose, supplemented with
2 mmol/l L-glutamine, 100 μmol/l non-essential amino
acids (NEAA), 100 U/ml penicillin and 100 μg/ml
streptomycin) for 16 h at 37°C and 5% CO2. Electric-field
stimulation was performed for 30 min at 40 V with a
frequency of 2 Hz and a pulse duration of 15 ms.
Content of adenosine phosphates Pelleted HL-1 cells were
freeze dried then extracted with 1.3 mol/l perchloric acid
and neutralised with 1 mol/l KHCO3. Thereafter, concen-
trations of ATP, ADP and AMP were determined by high-
performance liquid chromatography as described previously
by Luiken et al. [12].
Transfection of HL-1 cells Plates (48 well) were seeded
with 80,000 cells per well 24 h before transfection with
double-stranded siRNAs. Transfection of siRNA was done
with 25 pmol siRNA and 1 μl Lipofectamine-2000
(Invitrogen, San Diego, CA, USA) per well in antibiotic-
and noradrenaline-free culture medium. Cotransfection of
siRNAwithpCMV-GLUT4myc was performed with 20 pmol
siRNA, 0.15 μg plasmid DNA and 1 μl Lipofectamine-2000
per well in antibiotic- and noradrenaline-free culture medium.
After6h,themediumwaschangedtoregularculturemedium.
Cell lysis or functional assays were performed 48 h after
siRNA transfection.
CD36 cell surface staining Plasmalemmal CD36 was
measured 48 h after transfection of siRNA into HL-1
cardiomyocytes. Prior to measuring CD36, cells were
incubated in depletion medium for 16 h at 37°C and 5%
CO2. Translocation of CD36 was induced by incubation with
200 nmol/l insulin or 1 μmol/l oligomycin, or by electric-
field stimulation with 2 Hz pacing for 30 min at 37°C and
5% CO2. Afterwards, cells were fixed with 4% (wt/vol.)
formaldehyde twice for 10 min at room temperature and
blocked for 1 h with PBS containing 1% (wt/vol.) non-fat
dried milk and 0.05% (vol./vol.) Tween 20. Cells were
incubated with an anti-CD36 antibody (1:2,000 in blocking
buffer) for 30 min at room temperature and subsequently
washed three times with blocking buffer. Next, cells were
incubated with a horseradish peroxidase (HRP)-linked
secondary antibody (1:4,000 in blocking buffer) for 30 min
at room temperature. After extensive washing with blocking
buffer and PBS, an ortho-phenylenediamine–H2O2 solution
was added as a substrate for the bound HRP. The reaction
was carried out at room temperature and stopped after
30 min by addition of 1 mol/l H2SO4. Colour development,
representative of the amount of CD36 present at the plasma
membrane, was quantified by measurement of the absor-
bance at 490 nm. The background signal of the control
(incubation without primary antibody) was subtracted from
the raw data.
GLUT4myc cell surface staining In contrast to CD36,
GLUT4 is a transmembrane protein without a large
extracellular epitope. Therefore, it cannot be detected by
an antibody when integrated with the plasma membrane.
This problem can be solved by overproduction of a
GLUT4 variant carrying an myc tag on its first extracel-
lular epitope [13]. When properly integrated with the
plasma membrane the myc epitope of GLUT4myc is
extracellular and can easily be detected. In our study,
plasmalemmal GLUT4myc was measured 48 h after
cotransfection of the plasmid coding for GLUT4myc and
the siRNAs. The staining of plasmalemmal GLUT4myc is
done with a primary antibody against myc and an
appropriate HRP-linked secondary antibody. Aside from
these details, the GLUT4myc surface staining is homolo-
gous to the method of CD36 cell-surface staining. The
background signal of the controls (1, incubation without
primary antibody; 2, untransfected cells) was subtracted
from the raw data.
Glucose and palmitate uptake Substrate uptake into HL-1
cardiomyocytes was measured 48 h after transfection of the
HL-1 cardiomyocytes seeded on pre-coated glass slides.
Serum-depleted cells were treated with 200 nmol/l insulin,
1 μmol/l oligomycin or electrical pacing (2 Hz) for 30 min
at 37°C. Subsequently, palmitate (coupled to BSA in a
palmitate/BSA ratio of 1:3) and deoxy-D-glucose were
added to final concentrations of 20 and 4 μmol/l,
respectively, with tracer amounts of [
14C]palmitate and
2-deoxy-D-[
3H]glucose. After 10 min, uptake was termi-
nated and unbound substrate removed by washing the cells
with ice-cold depletion medium containing 0.2 mmol/l phlor-
etin. After transfer of the glass slides into new culture dishes,
cells were lysed by addition of 1 mol/l NaOH. Subsequently,
incorporated glucose and palmitate were measured by
scintillation counting of
14Ca n d
3H.
Diabetologia (2010) 53:2209–2219 2211Cell lysis and western blotting Cell lysis and western
blotting were performed as described earlier by van Oort
et al. [14].
Statistics All data are presented as means ± SEM. Statis-
tical analysis was performed by using Student’s t test or
ANOVA (including Newman–Keuls multiple comparison
test) and statistical analysis software Prism 4 (GraphPad
Software). A p value of <0.05 was considered statistically
significant.
Results
Characterisation of HL-1 cells HL-1 cells have previously
been shown to produce the cardiac glucose transporters
GLUT1 and GLUT4 as well as the fatty acid transporter
CD36 [15, 16]. When comparing the production of the
different VAMP isoforms in mouse heart, skeletal muscle,
brain and HL-1 cells, we observed that VAMP isoforms 2,
3, 4, 5 and 7 are detectable in heart and skeletal muscle as
well as in HL-1 cells (Fig. 1a). However, as VAMP8 was
only detectable in mouse brain, it was not further
investigated.
A suitable approach to induce myocellular contractions
in vitro is electric-field stimulation, resulting in elevated
AMP levels and subsequent activation of AMPK [17]. HL-
1 cardiomyocyte cultures were also found to contract upon
electric-field stimulation using 40 V and 2 Hz pulses of
15 ms length. Under this condition, the AMP/ATP ratio
increased 2.1-fold (Table 1), leading to a subsequent
increase in phosphorylation of AMPK (2.8-fold) and ACC
(14.0-fold, p<0.05, n=3; Fig. 1b). Alternatively, ATP
depletion, as occurs during contraction, can be achieved by
incubation of cardiomyocytes with the F0F1-ATPase inhib-
itor oligomycin. Already low concentrations of oligomycin
(1 μmol/l) resulted in a 2.7-fold increase in the AMP/ATP
ratio and a robust increase in phosphorylation of AMPK and
ACC (3.6-fold and 11.3-fold, respectively; p<0.05,
n=3; Table 1,F i g .1b). The use of electric-field stimulation,
however, requires a disproportional expenditure compared
with the equivalent pharmacological approach with oligomy-
cin. Therefore, the systematic screening for VAMP isoforms
involved in AMPK-mediated transporter translocation was
performed with oligomycin and the results evaluated after-
wards with electric-field-stimulated cells. Oligomycin treat-
ment did not increase apoptosis in HL-1 cells as measured on
the level of cleaved caspase-3 (Fig. 1c). In contrast, cleaved
caspase-3 accumulated in cells treated with staurosporine, a
known initiator of cell death [18]. Activation of insulin
signalling was investigated by measuring protein kinase
B/AKT Ser473 phosphorylation, which was elevated
3.3-fold by 200 nmol/l insulin (Fig. 1d). Insulin treatment
did not interfere with AMPK signalling, nor did oligomycin
interfere with insulin signalling (Fig. 1d).
Transfection of HL-1 cells with pCMV-GLUT4myc led
to a robust overproduction of GLUT4myc that did not
interfere with endogenous CD36 production (Fig. 2a). Each
of the stimuli induced the translocation of GLUT4myc
(Fig. 2b) and CD36 (Fig. 2c) to the plasma membrane to
comparable magnitudes. Subsequent substrate uptake,
especially palmitate uptake, has to be corrected for the
non-protein-mediated uptake component. This can be done
by subtraction of the uptake rate that is not inhibited by
phloretin, a general inhibitor of protein-mediated membrane
transport [19]. In HL-1 cells, basal glucose uptake was
entirely inhibited by phloretin (Fig. 2d), while basal
palmitate uptake was inhibited by 52% (Fig. 2e). For
VAMP2
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VAMP8
VAMP5
HL-1
ab
Control Oligomycin
1μmol/l
2 Hz
stimulation
Caveolin−3
pAMPK (Thr172)
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Staurosporin
5 μmol/l  5 μmol/l  1 μmol/l 
Oligomycin
pAMPK
Cleaved
caspase-3
H SkM Br
cd
Control Insulin
200 nmol/l 
Oligomycin
1μmol/l 
pAkt (Ser473)
pAMPK (Thr172)
pACC (Ser79)
β-Actin
β-Actin
Fig. 1 Characterisation of HL-1 cardiomyocytes. a HL-1 lysates and
homogenates from mouse heart (H), skeletal muscle (SkM) and brain
(Br) were separated with SDS-PAGE and blotted against VAMP
isoforms 2–8. b AMPK activation in HL-1 cells by electric-field
stimulation. Serum-depleted cells were electrically paced for 30 min
with 40 V, 2 Hz and 15 ms pulses. Lysates were separated by SDS-
PAGE and blotted against pAMPK and pACC. Cells treated with
1 μmol/l oligomycin served as a positive control for AMPK and ACC
phosphorylation. c Apoptosis in HL-1 cells. Serum-depleted HL-1
cells were stimulated with two concentrations of oligomycin for
30 min. Lysates were separated by SDS-PAGE and blotted for
pAMPK and cleaved caspase-3. Staurosporine, 5 μmol/l, was used
as a positive control for apoptosis-induced cleaved caspase-3
accumulation. d Selectivity of insulin and oligomycin stimulation on
protein phosphorylation. Serum-depleted cells were treated with
200 nmol/l insulin or 1 μmol/l oligomycin for 30 min. Lysates were
separated by SDS-PAGE and blotted for pAKT, pAMPK and pACC.
Representative western blots are shown
2212 Diabetologia (2010) 53:2209–2219comparison, sulfo-N-succinimidyloleate (SSO), a specific
inhibitor of CD36, inhibited palmitate uptake by 33%
(Fig. 2e), while not affecting glucose uptake (Fig. 2e).
Hence, CD36 contributes >60% of the protein-mediated
component of basal palmitate uptake. When the cells were
treated with insulin, both glucose and palmitate uptake were
stimulated (Fig. 2d,e). When SSO was added, insulin-
stimulated palmitate uptake, but not glucose uptake, was
completely prevented (Fig. 2e). This confirms that CD36
translocation is responsible for the stimulus-induced increase
Table 1 HPLC analysis of adenosine phosphates in HL-1 cells
Variable Basal Treatment
a
Insulin Electric-field stimulation Oligomycin
ATP (μmol/g dry weight) 1.57±0.05 1.55±0.13 1.15±0.22* 0.69±0.03*
ADP (μmol/g dry weight) 1.77±0.28 1.25±0.20 1.70±0.19 1.25±0.05
AMP (μmol/g dry weight) 0.27±0.09 0.21±0.01 0.41±0.10 0.31±0.05
AMP/ATP 0.17±0.06 0.14±0.02 0.36±0.18* 0.45±0.09*
Lysates were freeze dried and high-energy phosphates determined by HPLC analysis
aSerum-depleted cells were treated with 200 nmol/l insulin, electric-field stimulation (2 Hz) or 1 μmol/l oligomycin for 30 min
*p<0.05 vs basal level
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Fig. 2 Substrate transporters and transport in HL-1 cardiomyocytes.
a HL-1 cells were transfected with either pCMV (control) or pCMV-
GLUT4myc 24 h after seeding. After a further 48 h cells were lysed
and the lysates separated by SDS-PAGE and blotted for GLUT4, myc
and CD36. Caveolin 3 (Cav3) served as a loading control.
Representative western blots are shown. b, c At 48 h after transfection,
serum-depleted cells were treated with 200 nmol/l insulin, electric-
field stimulation or 1 μmol/l oligomycin for 30 min. Afterwards,
plasmalemmal GLUT4myc (b) and CD36 (c) were detected by
immunostaining. d, e Serum-depleted cells were incubated with
DMSO (control), 0.2 mmol/l phloretin or 0.5 mmol/l SSO for
30 min. Unbound SSO was washed away and cells were stimulated
with 200 nmol/l insulin for 30 min in the continued presence of
phloretin (where indicated). Afterwards, the cells were incubated with
a substrate mix containing 2-deoxy-D-[
3H]glucose and [
14C]palmitate
for 10 min. (d) Glucose uptake and (e) palmitate uptake were
quantified by scintillation counting of the cell lysates. The uptake
component that was not inhibited by phloretin, i, presents non-protein-
mediated uptake (i.e. passive diffusion), and the uptake component
that was not inhibited by SSO, ii, presents the component of palmitate
uptake that was independent of CD36. Data are mean values ± SEM
of three independent experiments (n=3), with triplicate measurements
for each condition. *Statistically different from corresponding basal
value (p<0.05)
Diabetologia (2010) 53:2209–2219 2213in palmitate uptake. However, total palmitate uptake has
to be corrected for the passive diffusion component
(phloretin) of palmitate uptake. Therefore, palmitate
uptake values in a phloretin-treated group were routinely
subtracted from the total palmitate uptake in order to
determine facilitated palmitate uptake. Such correction for
the passive diffusion component is not necessary in the
case of glucose uptake, which is almost entirely blunted
by phloretin (Fig. 2d).
Abundance of GLUT4myc and CD36 at the plasma
membrane after VAMP knockdown HL-1 cells can effi-
ciently be transfected with siRNAs using lipid-based
transfection reagents (Fig. 3a). The transfection of the
selected siRNAs directed against VAMP isoforms 2, 3, 4, 5
and 7 led to a protein repression of 81%, 54%, 46%, 62%
and 55% (p<0.05, n=3), respectively, and had no cross-
reactivity between the different VAMP isoforms as verified
by western blot analysis (Fig. 3b).
As found with the non-transfected HL-1 cells (Fig. 2),
insulin and oligomycin also increased the plasmalemmal
amount of GLUT4myc after transfection with a non-coding
siRNA, by 1.4- and 1.6-fold, respectively (Fig. 4a,b).
Furthermore, plasmalemmal CD36 was increased 1.3-fold
and 1.6-fold, respectively (Fig. 4c). After VAMP2 knock-
down, basal CD36 presence at the plasma membrane was
increased 1.2-fold. Furthermore, the insulin-stimulated
increase of both GLUT4myc and CD36 at the plasma
membrane was completely inhibited. In contrast,
oligomycin-stimulated GLUT4myc and CD36 translocation
was not affected. VAMP3 knockdown had no effect on
insulin-stimulated transporter translocation but completely
inhibited oligomycin-stimulated GLUT4myc and CD36
translocation. Differences between GLUT4myc and CD36
translocation were observed after VAMP4 knockdown.
While insulin- and oligomycin-stimulated GLUT4myc
translocation remained unaffected, stimulation of CD36
translocation by both compounds was completely inhibited.
VAMP5 knockdown increased basal GLUT4myc abundance
a tt h ep l a s m am e m b r a n e1 . 2 -fold, while completely
inhibiting the stimulatory effects of both insulin and
oligomycin on translocation of this transporter. Simulta-
neously, insulin-stimulated CD36 translocation was com-
pletely inhibited, whereas oligomycin-stimulated CD36
translocation was not affected. VAMP7 knockdown in-
creased the basal presence of GLUT4myc at the plasma
membrane by 1.5-fold. In spite of the increased basal
plasmalemmal content of GLUT4myc in VAMP7-silenced
cells, the ability of insulin and oligomycin to stimulate
GLUT4myc translocation was largely maintained. In
contrast to VAMP5 knockdown, VAMP7 knockdown had
no effect on CD36 translocation.
When measuring substrate uptake, changes in the
plasmalemmal abundance of GLUT4myc and CD36 gener-
ally resulted in concomitant changes in glucose and
palmitate uptake (Fig. 5), indicating that the dynamics of
substrate utilisation directly correlate with the abundance of
both transporters at the plasma membrane. However, the
effects of VAMP2 knockdown on insulin-stimulated glucose
uptake and of VAMP3 knockdown on oligomycin-
siRNA
nc VAMP2 VAMP3 VAMP4 VAMP5 VAMP7
IB:
VAMP2
VAMP3
VAMP4
VAMP7
VAMP5
siRNA
(pmol/well)
LM
0
5
10
20
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ab
Akt
loading control 
Fig. 3 Transfection and knock-
down of genes encoding VAMP
isoforms. a HL-1 cells were
transfected with different con-
centrations of fluorescence-
labelled siRNA 24 h after
seeding. Transfection efficiency
was microscopically determined
6 h after transfection by assess-
ment of the incorporated
fluorescence. b HL-1 cells were
transfected with siRNAs against
VAMP2–8 24 h after seeding.
After a further 48 h, cells were
lysed and the lysates separated
by SDS-PAGE and subsequently
blotted for each VAMP isoform.
Protein kinase B/AKT (AKT)
served as a loading control.
Representative western blots are
shown. FM, fluorescence
microscopy; LM, light
microscopy; nc, non-coding; IB,
immuno blot
2214 Diabetologia (2010) 53:2209–2219stimulated glucose uptake (Fig. 5b) were significantly lower
than the effects measured on GLUT4myc translocation
(Fig. 4b). Furthermore, VAMP5 knockdown had a signifi-
cantly greater effect on glucose uptake than on GLUT4myc
translocation. To test whether these discrepancies between
GLUT4myc translocation and glucose uptake might be due
to GLUT1-mediated glucose uptake, we used the specific
GLUT4 inhibitor indinavir, which does not interfere with
GLUT1-mediated glucose uptake [20]. In non-coding-
siRNA-transfected cells, indinavir inhibited basal glucose
uptake by 41% (Fig. 6). In VAMP5-silenced cells treated
with indinavir basal glucose uptake was elevated by 1.5-fold
compared with basal uptake by the indinavir-treated control
cells (Fig. 6). These findings indicate that GLUT1 is an
important contributor to basal glucose uptake, and that its
quantitative involvement is increased upon VAMP5 silenc-
ing. However, insulin- or oligomycin-stimulated glucose
uptake was completely inhibited by indinavir treatment
(Fig. 6), demonstrating that GLUT4 is entirely responsible
for the increase in stimulus-induced glucose uptake without
any role of GLUT1. Just as in VAMP5-depleted cells in the
absence of indinavir (Fig. 5b), indinavir-treated cells lacking
VAMP5 did not display altered glucose uptake upon
stimulation with insulin or oligomycin (Fig. 6).
Effects of VAMP3 knockdown on electric-field stimulated
GLUT4myc and CD36 translocation As mentioned above,
oligomycin was used to increase the intracellular AMP/ATP
ratio and activate AMPK signalling. Therefore, the effects
of VAMP gene knockdown on oligomycin-stimulated
transporter translocation and substrate uptake are expected
to be found also in contraction-induced transporter translo-
cation. To verify this, we measured GLUT4myc and CD36
translocation in VAMP3-silenced cells that were contracted
using electric-field stimulation (Fig. 7a). As expected, the
translocation of both GLUT4myc and CD36 were com-
pletely inhibited after VAMP3 knockdown (Fig. 7b, c).
Hence, VAMP3 is similarly involved in both oligomycin-
and contraction-induced GLUT4myc and CD36 translo-
cation, confirming that both stimuli use the same
trafficking machinery to move these transporters to the
cell surface. By inference, the effects of knockdown of
genes encoding other VAMP isoforms on oligomycin-
stimulated transporter translocation can, most likely, be
extrapolated to contraction-stimulated GLUT4myc and
CD36 translocation.
Discussion
GLUT4 and CD36 dynamically traffic between subcellular
compartments and the plasma membrane in cardiomyo-
cytes. Insulin and contraction trigger the accumulation of
both substrate transporters at the plasma membrane to
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Fig. 4 Plasmalemmal abun-
dance of substrate transporters
after knockdown of genes
encoding VAMP isoforms.
a HL-1 cells were co-transfected
with VAMP2–7 siRNAs and
pCMV-GLUT4myc 32 h after
seeding. After a further 28 h the
cells were serum depleted for
16 h and subsequently treated
with 200 nmol/l insulin or
1 μmol/l oligomycin for 30 min
(white bars, basal; grey bars,
insulin; black bars, oligomycin).
Afterwards, plasmalemmal
GLUT4myc (b) and plasmalem-
mal CD36 (c) were detected by
immunostaining. Data are mean
values ± SEM of six indepen-
dent experiments (n=6), with
triplicate measurements for each
condition. Statistically different
from corresponding value in
control group (*p<0.05);
statistically different from
corresponding basal
value (
†p<0.05). nc, non-coding
Diabetologia (2010) 53:2209–2219 2215increase the uptake of glucose and LCFA. In the present
study, we investigated the involvement of VAMPs in the
process of GLUT4 and CD36 translocation to the plasma
membrane on stimulation with insulin and increased
AMPK activity. We identified myocardial VAMP isoforms
that: (1) are shared by the GLUT4 and CD36 trafficking
machineries but discriminate between insulin-stimulated
and contraction-induced translocation processes; (2) dis-
criminate between CD36 and GLUT4 traffic; and (3)
contribute differently to the subcellular distribution of these
substrate transporters. Interestingly, it is of note that despite
residual levels of VAMP of 20–50%, the inhibitory effects of
these gene knockdowns on stimulated transporter transloca-
tion were complete. More specifically, we observed no linear
correlation between knockdown efficiency of each of the
VAMPs and changes in plasmalemmal transporter abundance
when comparing the results from the individual knockdown
experiments.ThisindicatesthatGLUT4andCD36trafficking
in cardiomyocytes is very sensitive to already small modu-
lations of VAMP abundance.
Selective VAMPs are necessary for both GLUT4 and CD36
translocation, but discriminate between insulin- and
contraction-induced translocation Previous studies showed
remarkable similarity between the regulation of GLUT4
and CD36 translocation, especially in the sense that both
depend on the same signalling processes (i.e. the
phosphoinositide-3 kinase [PI3K]/AKT axis upon insulin
stimulation and the LKB1/AMPK axis upon contraction
stimulation [1]). The present study further reveals that
selected VAMPs (i.e. VAMP2, VAMP3 and VAMP5) are
involved in the trafficking of both GLUT4 and CD36.
Insulin-stimulated translocation of GLUT4 and CD36 was
dependent on VAMP2 and VAMP5. The role of VAMP2 in
insulin-stimulated GLUT4 translocation has been well
established in skeletal muscle cells and adipocytes [9, 21].
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Fig. 5 Substrate uptake after knockdown of genes encoding VAMP
isoforms. a HL-1 cells were transfected with siRNAs 24 h after
seeding. After a further 32 h the cells were serum depleted for 16 h
and subsequently treated with 200 nmol/l insulin or 1 μmol/
l oligomycin for 30 min (white bars, basal; grey bars, insulin; black
bars, oligomycin). Afterwards, the cells were incubated with a
substrate mix containing 2-deoxy-D-
3H-glucose and
14C-palmitate for
10 min. Glucose uptake (b) and palmitate uptake (c) were quantified
by scintillation counting of the cell lysates and corrected for the
uptake component that could not be inhibited by phloretin (passive
diffusion component). Data are mean values ± SEM of six
independent experiments (n=6), with triplicate measurements for each
condition. Statistically different from corresponding value in control
group (*p<0.05); statistically different from corresponding basal value
(
†p<0.05). nc, non-coding
2216 Diabetologia (2010) 53:2209–2219However, the additional involvement of VAMP5 discloses a
difference between cardiomyocytes and adipocytes [21]. Still,
the function of VAMP5 is rather complex as it is additionally
involved in contraction-induced GLUT4 translocation. The
mechanism by which insulin signals to VAMP2 and VAMP5
could include PI3K-mediated activation of protein kinase C
ζ [22]. The notion that both VAMP2 and VAMP5 are
necessary for insulin-stimulated transporter translocation
indicates that these VAMPs fulfil non-complementary roles
in this process. Perhaps these VAMPs operate at different
steps in the translocation process.
In contrast to the findings with VAMP2, we found VAMP3
tobeselectivelyinvolvedincontraction-inducedtranslocation
of both GLUT4 and CD36. Previous evidence for a role of
VAMP3 in substrate-transporter translocation comes from
studies in which VAMP3, just like VAMP2, has been shown
to co-localise with GLUT4 [23, 24], whereas this has not yet
been determined for CD36. However, functional evidence of
the involvement of VAMP3 in contraction-induced trans-
porter translocation is lacking in these previous studies. Our
observation that VAMP3 is involved in contraction-induced
transporter translocation is, however, difficult to reconcile
with a study in rat skeletal muscle in which VAMP2,
VAMP5 and VAMP7, but not VAMP3, migrated to the
plasma membrane together with GLUT4 upon contraction
stimulation [24]. The observation by Rose et al. that the
plasmalemmal presence of VAMP3 is not increased upon
contraction might be explained by a rapid dissociation of the
VAMP3-containing SNARE complex by NSF and SNAP at
the plasma membrane [25, 26]. However, tissue differences
might also explain these controversial observations.
Taken together, the shared involvement of distinct VAMPs
in both GLUT4 and CD36 translocation indicates that CD36
translocation, just like GLUT4 translocation, is a vesicle-
mediated process dependent on SNARE-complex formation.
Moreover, this shared involvement further emphasises the
similarity in the protein machinery regulating both processes.
Selective VAMPs can discriminate between GLUT4 and
CD36 translocation Besides the shared involvement of
specific VAMPs in both GLUT4 and CD36 translocation,
there are also VAMPs that discriminate between GLUT4 and
CD36 translocation. We found VAMP4 to be involved
specifically in CD36 translocation induced either by insulin
or contraction. Hence, this VAMP isoform is an essential
component of the CD36-dedicated trafficking machinery that
translocates CD36 to the plasma membrane independently
from GLUT4. VAMP5 is specifically involved in contraction-
induced translocation of GLUT4, but not CD36. This
contrasts with the involvement of VAMP5 in insulin-induced
translocation of both transporters and shows that the involve-
ment of VAMP5 in the regulation of transporter translocation
is complex. Furthermore, the function of VAMP5 appears to
be cell-type specific. While VAMP5 is not involved in
GLUT4 trafficking in adipocytes [21], we and others could
show its involvement in GLUT4 translocation in contracting
myocytes [24].
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lardistribution ofsubstrate transporters Trafficking proteins
are not only involved in stimulus-induced translocation
processes, but also in the subcellular retention of a given
recycling protein, so that upon termination of the stimulus,
this protein returns into its intracellular storage compart-
ment [5]. Hence, VAMPs might not only be involved in the
translocation of GLUT4 and CD36 to the plasma membrane
but also in their intracellular sorting. A reduction in specific
VAMPs could result in an increased basal presence of the
substrate transporters at the plasma membrane, either
through unregulated dispersion or inhibited internalisation.
The present findings indicate that VAMP5 and VAMP7
mediate basal GLUT4 retention. Interestingly, studies in
C2C12 myoblasts have revealed the presence of VAMP5 at
the plasma membrane [27]. Combining this finding with the
present data suggests that the plasmalemmal presence of
VAMP5 is important in GLUT4 internalisation. As we also
established that VAMP5 is additionally involved in insulin-
and contraction-induced GLUT4 translocation, VAMP5
appears to have a dual function in the regulation of GLUT4
distribution. Furthermore, we observed a discrepancy be-
tween GLUT4 abundance at the plasma membrane and
glucose uptake in VAMP5-depleted cells: the latter was
disproportionally increased. This discrepancy is likely to be
attributed to GLUT1, which is the second most important
glucose transporter in the heart [28, 29]. Inhibition of
GLUT4-mediated glucose uptake by indinavir revealed that
the residual glucose uptake (via GLUT1) was increased by
1.5-fold in VAMP5-depleted cells. Therefore, VAMP5 might
be involved in GLUT1 internalisation as well as GLUT4
internalisation under basal conditions. Alternatively, plasma-
lemmal GLUT1 might be upregulated in VAMP5-depeleted
cells as a secondary effect to compensate for the loss of
plasmalemmal GLUT4. This has already been observed in
cardiomyocytes and adipocytes lacking GLUT4 [30, 31].
Furthermore, a compensatory action of GLUT1 might serve
as an explanation for the incomplete inhibition of insulin-
stimulated glucose uptake in VAMP2-depleted cells and of
contraction-stimulated glucose uptake in VAMP3-depleted
cells in comparison with complete inhibition of GLUT4
translocation in both cases.
GLUT4, but not CD36, also accumulated at the plasma
membrane after VAMP7 knockdown, and even to a markedly
greater extent than after VAMP5 knockdown. However, in
contrast to VAMP5 knockdown, insulin and oligomycin
further increased the sarcolemmal abundance of GLUT4 in
VAMP7-depleted cells. Hence, VAMP7 solely functions in
GLUT4 internalisation and, unlike VAMP5, has no addi-
tional role in stimulus-induced GLUT4 translocation.
We also unveiled that a VAMP isoform—VAMP2—is
involved in basal CD36 retention. This ability of VAMP2 to
reduce basal levels of CD36 at the plasma membrane is not
accompanied by a similar effect of this VAMP isoform on
basal GLUT4 retention. Therefore, next to VAMP5 and
VAMP7, VAMP2 knockdown also specifically increases the
sarcolemmal presence of one of the two transporters under
basal conditions. Because we also found VAMP2 to be
involved in insulin-stimulated CD36 translocation, this
additional involvement in basal CD36 retention points to
a dual role of VAMP2 in the regulation of CD36 trafficking.
Hence, the dual role of VAMP2 in CD36 trafficking mirrors
the dual role of VAMP5 in GLUT4 traffic, and further
indicates that both processes are similarly regulated though,
in part, by different VAMP isoforms.
Concluding remarks These findings indicate the potential of
VAMPs to serve as targets for the so-called metabolic
modulation therapy [32, 33]. For instance, pharmacological
strategies to stimulate cardiac glucose uptake via increasing
myocardial VAMP2 production or decreasing myocardial
VAMP4/VAMP7 production is expected to be beneficial for
the diabetic heart in which glucose uptake is repressed in
favour of LCFA. Interestingly, VAMP2-silenced HL-1 cells
resemble insulin-resistant cardiomyocytes because: (1) use of
LCFA is increased already in the basal state; (2) insulin has
lost the ability to stimulate LCFA and glucose uptake; but (3)
contraction-induced glucose and LCFA uptake are unim-
paired. Similar changes occur in the cardiac and skeletal
muscle of insulin-resistant obese Zucker rats [2, 34].
Furthermore, VAMP2 production is decreased in the
retinas from streptozotocin-diabetic rats [35]a n di n
insulin-secreting cells after 72 h exposure to palmitate
[36]. Whether inhibition of VAMP2 also takes place in the
diabetic heart remains to be determined.
Acknowledgements This study was supported by the European
Community (Integrated Project LSHM-CT-2004-005272, Exgenesis),
the transnational University Limburg, the Natural Sciences and
Engineering Research Council of Canada, and the Heart and Stroke
Foundation of Ontario. A. Bonen is Canada Research Chair in
Metabolism and Health.
Duality of interest The authors report that there is no duality of
interest associated with this manuscript.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Schwenk RW, Luiken JJ, Bonen A, Glatz JF (2008) Regulation of
sarcolemmal glucose and fatty acid transporters in cardiac disease.
Cardiovasc Res 79:249–258
2218 Diabetologia (2010) 53:2209–22192. Coort SL, Hasselbaink DM, Koonen DP et al (2004) Enhanced
sarcolemmal FAT/CD36 content and triacylglycerol storage in
cardiac myocytes from obese Zucker rats. Diabetes 53:1655–1663
3. Russell LK, Finck BN, Kelly DP (2005) Mouse models of
mitochondrial dysfunction and heart failure. J Mol Cell Cardiol
38:81–91
4. Ouwens DM, Diamant M, Fodor M et al (2007) Cardiac
contractile dysfunction in insulin-resistant rats fed a high-fat diet
is associated with elevated CD36-mediated fatty acid uptake and
esterification. Diabetologia 50:1938–1948
5. Hong W (2005) SNAREs and traffic. Biochim Biophys Acta
1744:493–517
6. Sollner T, Bennett MK, Whiteheart SW, Scheller RH, Rothman JE
(1993) A protein assembly–disassembly pathway in vitro that may
correspond to sequential steps of synaptic vesicle docking,
activation, and fusion. Cell 75:409–418
7. Trimble WS, Cowan DM, Scheller RH (1988) VAMP-1: a
synaptic vesicle-associated integral membrane protein. Proc Natl
Acad Sci USA 85:4538–4542
8. Zeng Q, Subramaniam VN, Wong SH et al (1998) A novel
synaptobrevin/VAMP homologous protein (VAMP5) is increased
during in vitro myogenesis and present in the plasma membrane.
Mol Biol Cell 9:2423–2437
9. Randhawa VK, Bilan PJ, Khayat ZA et al (2000) VAMP2, but not
VAMP3/cellubrevin, mediates insulin-dependent incorporation of
GLUT4 into the plasma membrane of L6 myoblasts. Mol Biol
Cell 11:2403–2417
10. KawanishiM,TamoriY,OkazawaH,ArakiS,ShinodaH,KasugaM
(2000) Role of SNAP23 in insulin-induced translocation of GLUT4
in 3T3-L1 adipocytes. Mediation of complex formation between
syntaxin4 and VAMP2. J Biol Chem 275:8240–8247
11. Randhawa VK, Thong FS, Lim DY et al (2004) Insulin and
hypertonicity recruit GLUT4 to the plasma membrane of muscle
cells by using N-ethylmaleimide-sensitive factor-dependent
SNARE mechanisms but different v-SNAREs: role of TI-VAMP.
Mol Biol Cell 15:5565–5573
12. Luiken JJ, Coort SL, Willems J et al (2003) Contraction-induced
fatty acid translocase/CD36 translocation in rat cardiac myocytes
is mediated through AMP-activated protein kinase signaling.
Diabetes 52:1627–1634
13. Wang Q, Khayat Z, Kishi K, Ebina Y, Klip A (1998) GLUT4
translocation by insulin in intact muscle cells: detection by a fast
and quantitative assay. FEBS Lett 427:193–197
14. van Oort MM, van Doorn JM, Bonen A et al (2008) Insulin-
induced translocation of CD36 to the plasma membrane is
reversible and shows similarity to that of GLUT4. Biochim
Biophys Acta 1781:61–71
15. Shuralyova I, Tajmir P, Bilan PJ, Sweeney G, Coe IR (2004)
Inhibition of glucose uptake in murine cardiomyocyte cell line
HL-1 by cardioprotective drugs dilazep and dipyridamole. Am J
Physiol 286:H627–H632
16. Palanivel R, Eguchi M, Shuralyova I, Coe I, Sweeney G (2006)
Distinct effects of short- and long-term leptin treatment on glucose
and fatty acid uptake and metabolism in HL-1 cardiomyocytes.
Metabolism 55:1067–1075
17. Luiken JJ, Willems J, van der Vusse GJ, Glatz JF (2001) Electro-
stimulation enhances FAT/CD36-mediated long-chain fatty acid
uptake by isolated rat cardiac myocytes. Am J Physiol Endocrinol
Metab 281:E704–E712
18. McNeill-Blue C, Wetmore BA, Sanchez JF, Freed WJ, Merrick
BA (2006) Apoptosis mediated by p53 in rat neural AF5 cells
following treatment with hydrogen peroxide and staurosporine.
Brain Res 1112:1–15
19. Luiken JJ, van Nieuwenhoven FA, America G, van der Vusse GJ,
Glatz JF (1997) Uptake and metabolism of palmitate by isolated
cardiac myocytes from adult rats: involvement of sarcolemmal
proteins. J Lipid Res 38:745–758
20. Rudich A, Konrad D, Torok D et al (2003) Indinavir uncovers
different contributions of GLUT4 and GLUT1 towards glucose
uptake in muscle and fat cells and tissues. Diabetologia 46:649–658
21. Williams D, Pessin JE (2008) Mapping of R-SNARE function at
distinct intracellular GLUT4 trafficking steps in adipocytes. J Cell
Biol 180:375–387
22. Braiman L, Alt A, Kuroki T et al (2001) Activation of protein
kinase C zeta induces serine phosphorylation of VAMP2 in the
GLUT4 compartment and increases glucose transport in skeletal
muscle. Mol Cell Biol 21:7852–7861
23. Dugani CB, Randhawa VK, Cheng AW, Patel N, Klip A (2008)
Selective regulation of the perinuclear distribution of glucose
transporter 4 (GLUT4) by insulin signals in muscle cells. Eur J
Cell Biol 87:337–351
24. Rose AJ, Jeppesen J, Kiens B, Richter EA (2009) Effects of
contraction on localization of GLUT4 and v-SNARE isoforms in
rat skeletal muscle. Am J Physiol Regul Integr Comp Physiol 297:
R1228–1237
25. Bar-On D, Winter U, Nachliel E et al (2008) Imaging the
assembly and disassembly kinetics of cis-SNARE complexes on
native plasma membranes. FEBS Lett 582:3563–3568
26. Winter U, Chen X, Fasshauer D (2009) A conserved membrane
attachment site in α-SNAP facilitates NSF-driven SNARE
complex disassembly. J Biol Chem 284:31817–31826
27. Zeng Q, Tran TT, Tan HX, Hong W (2003) The cytoplasmic
domain of Vamp4 and Vamp5 is responsible for their correct
subcellular targeting: the N-terminal extenSion of VAMP4
contains a dominant autonomous targeting signal for the trans-
Golgi network. J Biol Chem 278:23046–23054
28. Becker C, Sevilla L, Tomas E, Palacin M, Zorzano A, Fischer Y
(2001) The endosomal compartment is an insulin-sensitive
recruitment site for GLUT4 and GLUT1 glucose transporters in
cardiac myocytes. Endocrinology 142:5267–5276
29. FischerY, Thomas J, Sevilla Let al (1997) Insulin-inducedrecruitment
of glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac
myocytes. Evidence of the existence of different intracellular GLUT4
vesicle populations. J Biol Chem 272:7085–7092
30. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ (1995)
Cardiac and adipose tissue abnormalities but not diabetes in mice
deficient in GLUT4. Nature 377:151–155
31. Stenbit AE, Katz EB, Chatham JC et al (2000) Preservation of
glucose metabolism in hypertrophic GLUT4-null hearts. Am J
Physiol 279:H313–H318
32. Taegtmeyer H, Woods A (2003) Clinical trials report. Metabolic
modulation as a principle for myocardial protection. Curr Hyper-
tens Rep 5:443–444
33. Glatz JF, Bonen A, Ouwens DM, Luiken JJ (2006) Regulation of
sarcolemmal transport of substrates in the healthy and diseased
heart. Cardiovasc Drugs Ther 20:471–476
34. Luiken JJ, Arumugam Y, Dyck DJ et al (2001) Increased rates of
fatty acid uptake and plasmalemmal fatty acid transporters in
obese Zucker rats. J Biol Chem 276:40567–40573
35. VanGuilder HD, Brucklacher RM, Patel K, Ellis RW, Freeman
WM, Barber AJ (2008) Diabetes downregulates presynaptic
proteins and reduces basal synapsin I phosphorylation in rat
retina. Eur J Neurosci 28:1–11
36. Lovis P, Roggli E, Laybutt DR et al (2008) Alterations in
microRNA expression contribute to fatty acid-induced pancreatic
beta-cell dysfunction. Diabetes 57:2728–2736
Diabetologia (2010) 53:2209–2219 2219